None listed
Conditions
Brief summary
This pilot study is assessing the feasibility of delivering quality assured single-fraction (SF) stereotactic ablative radiotherapy (SABR) pathway for early-stage non-small-cell lung cancer (NSCLC) in a ‘One-Stop’ visit to Peter MacCallum Cancer Centre. Who is it for? You may be eligible for this study if you are over the age of 18 and are referred for SF SABR, have early stage (T1-T2 N0M0) NSCLC, based on CT and/or PET/CT imaging. Study details Participating in this research involves undergoing your SABR treatment according to a different timeframe to what would normally happen. It also involves completing a short anonymised survey after your treatment to provide feedback on your experience of the treatment. Your next visit is for the simulation scan which the treatment team uses to plan and design your treatment. This happens whether or not you are participating in the study. However, if you are not on the study, you go home after this scan and the team works on the plan in the background. You are called back for treatment approximately two weeks later and undergo treatment as an outpatient. If you choose to participate in the study your treatment will happen within the same visit, customised to one of two options based on your travel requirements: (1) If most convenient to attend for a morning planning CT scan, treatment will be delivered in the afternoon. There will be a gap of roughly 4-6 hours between scan and treatment. You are free to leave the hospital during this time. Total time in the hospital may be anywhere from approximately 2-8 hours on that day. (2) If most convenient to attend for an afternoon planning CT scan, treatment will be delivered the next morning. You will also meet with one of our nurse specialists who will also discuss arrangements for your followup after the treatment and give you printed information about this and the experience survey. You will be provided with a $50 voucher for the ‘Super Eight’ café on the ground floor at Peter Mac to cover the cost of beverages and/or meals on the day of your attendance. A follow-up consultation with your radiation oncologist will also be arranged approximately two weeks later. This can be arranged as a ‘virtual’ telehealth appointment if you prefer. It is hoped this research will contribute to the development of streamlined, patient-centred treatment pathways and improve access to timely, high-quality SABR, potentially enhancing health outcomes for patients with early-stage NSCLC.
Interventions
Patients over the age of 18 with early-stage non-small-cell lung cancer (NSCLC), referred for SABR (either histologically confirmed lung cancer and/or MDM recommendation), will undergo, consent CT simulation, contouring, planning and treatment all in one single visit. Once consented, treatment will happen within the same visit, customised to one of two options based on travel requirements:
(1) If most convenient to attend for a morning planning CT scan (30-60mins), treatment will be delivered i
Patients over the age of 18 with early-stage non-small-cell lung cancer (NSCLC), referred for SABR (either histologically confirmed lung cancer and/or MDM recommendation), will undergo, consent CT simulation, contouring, planning and treatment all in one single visit. Once consented, treatment will happen within the same visit, customised to one of two options based on travel requirements: (1) If most convenient to attend for a morning planning CT scan (30-60mins), treatment will be delivered in the afternoon. There will be a gap of roughly 4-6 hours between scan and treatment. Patients are free to leave the hospital during this time. Total time in the hospital may be anywhere from approximately 2-8 hours on that day. (2) If most convenient to attend for an afternoon planning CT scan, treatment will be delivered the next morning. CT simulation scan would take approximately 30-60mins, after which you are free to go home and then will be required to return the next morning for treatment. Total time across both days at the hospital can be approximately 2-8 hours. Patients will then be asked to complete a survey about their experience and have one telehealth follow-up consultation (20 mins) 2 weeks post SABR one-stop visit as part of routine clinical practice.
Sponsors
Peter MacCallum Cancer Centre
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult Patients (min 18 years old) Referred for SABR for either: Histologically-confirmed lung cancer and/or MDM Recommendation for empiric SABR based on clinical and radiological features which are deemed to represent lung cancer Staging is T1-T2 N0M0 based on CT and/or PET/CT imaging o Diagnostic imaging performed within 6 weeks of study enrolment Non-central tumour location (i.e. Gross Tumour Volume (GTV) at least 2cm from proximal bronchial tree) Provides informed consent Fit to attend for the length of time required, whether fully independent, or by spending some or all of this time with nursing care in the radiotherapy trolley bay.
Exclusion criteria
Inability to complete patient experience survey based on cognitive impairment or other comorbidities Lack of suitable diagnostic images which is an important screening tool as part of the preplanning stage Unable to meet Peter MacCallum Cancer Centre clinical goals for SF SABR based on virtual pre-planning Previous radiotherapy which may overlap with the current lesion planned for treatment Synchronous malignancy also planned for oncological treatment
Outcome results
None listed